Evidence map›Paper›PMID 42166711›Full record

ArticleThe Journal of experimental medicine2026

CSF1R-dependent CD169-positive macrophages locally constrain melanoma growth in the skin.

Yuki Honda Keith, Emily Duchini, Xufeng Lin, Wunna Kyaw, Felix G P Weninger, Rama Dhenni, Aiden Josiah Telfser, Abigail K Grootveld, Deborah Barkauskas, Angela Fontaine-Titley and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yuki Honda KeithPrecision Immunology Program, Garvan Institute of Medical Research , Sydney, Australia.ORCID 0000-0002-0171-6495
Emily DuchiniFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID 0009-0000-4345-5628
Xufeng LinFaculty of Medicine, St Vincent's Clinical School, University of New South Wales, Sydney, Australia.ORCID 0000-0002-3400-8700
Wunna KyawPrecision Immunology Program, Garvan Institute of Medical Research , Sydney, Australia.ORCID 0000-0003-1509-8656
Felix G P WeningerPrecision Immunology Program, Garvan Institute of Medical Research , Sydney, Australia.ORCID 0009-0001-9525-055X
Rama DhenniPrecision Immunology Program, Garvan Institute of Medical Research , Sydney, Australia.ORCID 0000-0001-9782-6666
Aiden Josiah TelfserPrecision Immunology Program, Garvan Institute of Medical Research , Sydney, Australia.ORCID 0009-0006-8830-291X
Abigail K GrootveldPrecision Immunology Program, Garvan Institute of Medical Research , Sydney, Australia.ORCID 0000-0001-8951-1963
Deborah BarkauskasFaculty of Medicine, St Vincent's Clinical School, University of New South Wales, Sydney, Australia.ORCID 0000-0002-1872-4109
Angela Fontaine-TitleyFaculty of Medicine, St Vincent's Clinical School, University of New South Wales, Sydney, Australia.ORCID 0000-0002-5032-8026
Shweta TikooDepartment of Dermatology, The Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-5850-8075
Rohit JainDepartment of Dermatology, The Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4905-462X
Wolfgang WeningerDepartment of Dermatology, The Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-3133-8699
John W FrewSchool of Clinical Medicine, University of New South Wales , Sydney, Australia.ORCID 0000-0001-5042-3632
Elissa K DeenickPrecision Immunology Program, Garvan Institute of Medical Research , Sydney, Australia.ORCID 0000-0002-9271-0004
Robert BrinkPrecision Immunology Program, Garvan Institute of Medical Research , Sydney, Australia.ORCID 0000-0002-9586-3655
Linda K MartinMelanoma Institute Australia, The University of Sydney , Sydney, Australia.ORCID 0000-0001-9519-7077
Tatyana ChtanovaFaculty of Science, School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia.ORCID 0000-0003-3419-4483
Leonard D GoldsteinFaculty of Medicine, St Vincent's Clinical School, University of New South Wales, Sydney, Australia.ORCID 0000-0003-4645-553X
Richard A ScolyerFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID 0000-0002-8991-0013
Georgina V LongFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID 0000-0001-8894-3545
Umaimainthan PalendiraFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID 0000-0002-1113-3306
Tri Giang PhanPrecision Immunology Program, Garvan Institute of Medical Research , Sydney, Australia.ORCID 0000-0002-4909-2984

Funding

Australian Cancer Research FoundationAustralian National Health and Medical Research Council APPID 1155678Australian National Health and Medical Research Council APPID 2003662Australian National Health and Medical Research Council APPID 2018514Australian National Health and Medical Research Council APPID 2026131Australian Research Council DP220102278Cancer Institute New South WalesJacqueline Goodnow & Barbara Hartley PrizeJapan Society for the Promotion of Science 21J40104Kinghorn FoundationUniversity of New South Wales
6 · The paper itself

Abstract

Macrophages in the skin reside in multiple distinct layers and perform various functions. Here, we show that CD169+ macrophages reside in the hypodermis and comprise the major skin myeloid cell population in the steady state. In a syngeneic melanoma model, CD169+ macrophages encapsulate growing melanomas and directly suppress their growth. CSF1R blockade depleted CD169+ macrophages in tumors and resulted in unrestrained growth. This local containment of tumor growth in the skin was independent of CD169+ subcapsular sinus macrophages in the tumor-draining lymph node and did not require B or T cells. Intravital imaging revealed engulfment and ingestion of live tumor cells by CD169+ macrophages. This phagocytosis did not require the phosphatidylserine receptor MERTK. CD169+ macrophages are also enriched in the hypodermis in skin biopsies from healthy human skin and melanoma. These data identify tissue-resident CD169+ macrophages as a potential cellular target to achieve innate immune containment and reinforce adaptive immune control of tumors.

Indexed as

MacrophagesMelanomaReceptors, Granulocyte-Macrophage Colony-Stimulating FactorSialic Acid Binding Ig-like Lectin 1Skin NeoplasmsAnimalsCell Line, Tumorc-Mer Tyrosine KinaseHumansMiceMice, Inbred C57BLPhagocytosisSkinc-Mer Tyrosine KinaseCsf1r protein, mouseReceptors, Granulocyte-Macrophage Colony-Stimulating FactorSialic Acid Binding Ig-like Lectin 1Siglec1 protein, mouse

Identifiers

PMID42166711
PMCPMC13193709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.